Metalloproteinase inhibitors

A compound of formula (I)

• wherein
• X is —COOH or —CONHOH
• n is 1, 2, 3 or 4;
• R2 is a C1-C12 alkyl,
• C2-C12 alkenyl,
• C2-C12 alkynyl,
• phenyl(C1-C6 alkyl)—,
• cycloalkyl(C1-C6 alkyl)—,
• cycloalkenyl(C1-C6 alkyl)—,
• phenoxy(C1-C6 alkyl)—,
• phenyl(C1-C6 alkyl)O(C1-C6 alkyl)—, or
• phenyl(C1-C6 alkyl)S(C1-C6 alkyl)—group
• any one of which may be optionally substituted by C1-C6 alkyl, trifluoromethyl, C1-C6 alkoxy, halo, cyano (—CN), phenyl, or substituted phenyl;
• or
• R3 represents the characterising group of a natural or non-natural α amino acid in which any functional groups may be protected;
• provided that R3 does not comprise a heterocyclic or heteroaryl group,
• R8 is hydrogen, C1-C6 alkyl, benzyl, acyl, optionally substituted phenyl, an amino protecting group, or a group —(CH2)mCOZ where m is an integer from 1 to 6, and Z represents OH, C1-C6 alkoxy or —NRxRy where Rx, Ry each independently represent hydrogen or C1-C6 alkyl;
• and;
• and
• R9 is optionally substituted C1-C6 alkyl, cycloalkyl, cycloalkenyl, di-(C1-C6 alkyl)amino, phenyl, or naphthyl, or
• R8 and R9 taken together represent a divalent C3-C6 alkylene or alkenylene group which may optionally be (i) substituted by an oxo group, and/or (ii) substituted by (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), cyano, trifluoromethyl, nitro, —COOH, —CONH2, —CONHRA or —CONRARA wherein RA is a (C1-C6)alkyl group, and/or (iii) fused to a phenyl group which itself may be substituted;
• Y is a group of formula (ID) or (IE)
• wherein:
• R4 represents
• (a) an optionally substituted cycloalkyl or cycloalkenyl ring;
• or
• (b) a phenyl or heteroaryl ring which may be fused to a benzene or heteroaryl ring, either or both of which rings may be substituted, and in which any ring nitrogen atom may be oxidised as an N-oxide, or
• (c) a group —CHRxRy wherein Rx and Ry each independently represents an optionally substituted phenyl or heteroaryl ring which may be linked covalently to each other by a bond or by a C1-C4 alkylene or C2-C4 alkenylene bridge;
• (d) a group of formula —(Z′—O)w—Z wherein Z′ is straight or branched C1-C6 alkyl optionally interrupted by one or more non-adjacent S and/or N atoms, w is an integer >1, and no continuous linear sequence of atoms in the group R4 is >12, or
• (e) a straight or branched C1-C6 alkyl group, optionally interrupted by one or more non-adjacent S and/or N atoms, which is substituted by at least two substituents of formula —(Z′″)x—(OZ)q wherein Z′″ is straight or branched C1-C6 alkyl optionally interrupted by one or more non-adjacent S and/or N atoms, x is 0 or 1, q is 1 or 2, and no continuous linear sequence of atoms in the group R4 is >12, or
• (f) hydrogen, C1-C6 alkyl, C1-C4 perfluoroalkyl, or a group D-(C1-C6 alkyl)—wherein D is hydroxy, C1-C6 alkoxy, C1-C6 alkylthio, acylamino, optionally substituted phenyl or heteroaryl, NH2, or mono- or di-(C1-C6 alkyl)amino or N-morpholino;
• or R3 and R4 taken together represent a divalent chain of formula —C(Ra)(Rb)—A—Alk—wherein Ra and Rb are independently hydrogen or C1-C6 alkyl, A″ is a bond, —O—, —S—, —S—S—, —NH— or —NRa— wherein Ra is C1-C6 alkyl, and Alk is C1-C6 alkylene;
• R5 is hydrogen or a C1-C6 alkyl group;
• R6 is hydrogen, C1-C6 alkyl, phenyl(C1-C6 alkyl), heterocyclyl(C1-C6 alkyl), optionally substituted phenyl, or optionally substituted heterocyclyl;
• R7 is is hydrogen or a C1-C6 alkyl group;
• or (when R7 is hydrogen) R3 and R7 taken together with the carbon atoms to which they are attached form a 2-hydroxycyclohexyl or C6 sugar (hexose) ring;
• or R6 and R7 taken together with the carbon atom to which they are attached form a 5 or 6-membered carbocyclic or heterocyclic ring;
• or a pharmaceutically acceptable salt, hydrate or solvate thereof.